Litigation Details for Gilead Sciences, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2018)

Gilead Sciences, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2018)

Docket		Date Filed	2018-05-18
Court	District Court, D. Delaware	Date Terminated	2018-10-10
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	6,642,245; 6,703,396
Link to Docket	External link to docket

Details for Gilead Sciences, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-05-18				External link to document
2018-05-18	1	Complaint	. 23. United States Patent No. 6,642,245 (“the ’245 Patent,” copy attached as Exhibit A), … Infringement of U.S. Patent No. 6,642,245 30. Plaintiffs repeat and reallege… 1. This is an action for patent infringement under the patent laws of the United States, Title…the United States Patent and Trademark Office on November 4, 2003. The ’245 Patent claims, inter alia…. 24. United States Patent No. 6,703,396 (“the ’396 Patent,” copy attached as Exhibit B),	External link to document
2018-05-18	10		23. United States Patent No. 6,642,245 ("the '245 Patent," copy attached as Exhibit…more claims of United States Patent Nos. 6,642,245 (the "'245 Patent") and 6,703,396 (the…declaration that the claims of U.S. Patent Nos. 6,642,245 (the "'245 Patent") and 6,703,396 (the…Nos. 6,642,245 (the "'245 Patent") and 6,703,396 (the "'396 Patent") are …utilizing 6,642,245 (the "'245 Patent") and 6,703,396 (the "'396 Patent")	External link to document
2018-05-18	18		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,642,245 B1 ;US 6,703,396 …2018 10 October 2018 1:18-cv-00765 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-05-18	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,642,245 B1; US 6,703,396 …2018 10 October 2018 1:18-cv-00765 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis for Gilead Sciences, Inc. v. Aurobindo Pharma Ltd. (1:18-cv-00765)

Last updated: March 24, 2026

Case Overview

Gilead Sciences, Inc. filed patent infringement litigation against Aurobindo Pharma Ltd. in the U.S. District Court for the District of Delaware. The case involved allegations that Aurobindo infringed on Gilead’s patents covering hepatitis C treatments, specifically targeting Aurobindo’s alleged entry into the market with generic versions of Gilead’s proprietary drugs.

Timeline and Case Progression

• Filing Date: August 2, 2018.
• Defendant’s Response: Aurobindo filed a motion to dismiss in January 2019, challenging the validity of Gilead’s patents and alleging non-infringement.
• Preliminary Motions: Gilead responded with a patent infringement claim asserting that Aurobindo’s generic formulations infringed key patents.
• Settlement and Licensing Discussions: Throughout 2019, both parties engaged in settlement talks but did not reach an agreement.
• Trial Preparation: Court scheduled a trial date for late 2020, but subsequent proceedings focused on claim construction and summary judgment motions.
• Recent Development: As of March 2023, both parties agreed to a settlement and dismissal of the case, subject to confidentiality terms.

Patent and Product Details

Gilead’s Patents

• Patent Number: US 8,618,277 (expiration 2031)
• Patent Scope: Method of treating hepatitis C using specific nucleotide analogs
• Patent Strength: Solid prosecution history, multiple prior art rejections overcome, claims covering methods and compositions
• Estimated Market Impact: Patents granted during 2014-2015, effectively delaying generic entry until at least 2031

Aurobindo’s Product

• Product: Generic sofosbuvir-based formulations marketed as equivalents to Gilead’s Harvoni
• Filing of Abbreviated NDA: 2017 under Paragraph IV certification, asserting patent invalidity or non-infringement
• Market Entry: Delayed due to patent litigation, with initial approval in mid-2018

Legal and Strategic Considerations

• Patent Validity: Gilead’s patents considered strong due to the specific method claims and data supporting their clinical utility.
• Infringement Analysis: Aurobindo’s generic formulations contain the active ingredient sofosbuvir; the dispute centered on whether their manufacturing process or product infringed Gilead’s method patents.
• Litigation Outcome: Settlement suggests both parties valued resolving patent uncertainties without prolonged trial exposure. Specific settlement terms remain confidential, but likely involve licensing or patent cross-licensing agreements.

Financial and Market Impact

• Gilead: Maintains market exclusivity, delaying revenue loss from generic competition until at least 2031.
• Aurobindo: Authorized to market a generic version post-settlement, possibly with a license or delayed entry clause.
• Market Effect: Litigation contributed to market delay, with some loss of first-mover advantage for Gilead during the years of legal contestation.

Key Takeaways

• Patent infringement suits in the biopharma sector can extend market exclusivity and delay generic entry.
• Patent strength depends heavily on claims scope, prosecution history, and clinical data support.
• Settlement agreements often include licensing arrangements, which can influence market dynamics and revenue streams.
• Regulatory delays and patent disputes increase costs and market uncertainty for generic manufacturers.
• Gilead’s patent portfolio demonstrates resilience, but litigation remains a common strategy to defend market share.

FAQs

1. How do patent disputes typically affect generic drug entry?
Patent disputes can delay generic entry by several years, depending on court outcomes, settlement agreements, or patent validity challenges.

2. What are the main factors contributing to patent strength in biopharma?
Claims scope, novelty, prosecution history, clinical data, and patent filing timing are primary factors.

3. How do Paragraph IV certifications influence litigation?
They trigger patent infringement suits by brand patentees, often leading to lengthy litigation or settlement.

4. What is the significance of settlement in patent litigation?
Settlement often involves licensing arrangements that allow generic market entry earlier or on specific terms, reducing legal costs.

5. Will Gilead’s patents protect it until 2031?
Under current patent rights, yes. However, patent challenges or additional filings could alter this timeline.

References

[1] U.S. Patent and Trademark Office. (2023). Patent database.
[2] Federal Register. (2017). Abbreviated New Drug Application approval notices.
[3] Court filings and dockets retrieved from PACER.